Journal of Cancer Research and Clinical Oncology

, Volume 134, Issue 9, pp 1037–1042 | Cite as

Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

  • Katerina Vrzalikova
  • Joseph Skarda
  • Jiri Ehrmann
  • Paul G. Murray
  • Eduard Fridman
  • Jury Kopolovic
  • Petra Knizetova
  • Marian Hajduch
  • Jiri Klein
  • Vitezslav Kolek
  • Lenka Radova
  • Zdenek Kolar
Original Paper



Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes.


Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS.


Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10−6) and stage IV (P = 10−5) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05).


Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.


Tissue microarray Non-small cell lung cancer Bmi-1 oncogene Polycomb genes 


  1. Bea S, Tort F, Pinyol M et al (2001) BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409–2412PubMedGoogle Scholar
  2. Breuer RH, Snijders PJ, Smit EF et al (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736–743PubMedCrossRefGoogle Scholar
  3. Breuer RH, Snijders PJ, Sutedja GT et al (2005) Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48:299–306PubMedCrossRefGoogle Scholar
  4. Broers JL, Viallet J, Jensen SM et al (1993) Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 9:33–43PubMedGoogle Scholar
  5. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP et al (2005) Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 19:1438–1443PubMedCrossRefGoogle Scholar
  6. Denlinger CE, Rundall BK, Jones DR (2004) Modulation of antiapoptotic cell signaling pathways in non-small cell lung cancer: the role of NF-kappaB. Semin Thorac Cardiovasc Surg 16:28–39PubMedCrossRefGoogle Scholar
  7. Dimri GP, Martinez JL, Jacobs JJ et al (2002) The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62:4736–4745PubMedGoogle Scholar
  8. Doyle LA (1993) Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20:326–337PubMedGoogle Scholar
  9. Dubey S, Schiller JH (2005) Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 10:282–291PubMedCrossRefGoogle Scholar
  10. Dukers DF, van Galen JC, Giroth C et al (2004) Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am J Pathol 164:873–881PubMedGoogle Scholar
  11. Dutton A, Woodman C, Chukwuma M et al (2007) Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 109:2597–2603PubMedCrossRefGoogle Scholar
  12. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503–1521PubMedCrossRefGoogle Scholar
  13. Guney I, Wu S, Sedivy JM (2006) Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16 (INK4a). Proc Natl Acad Sci USA 103:3645–3650PubMedCrossRefGoogle Scholar
  14. Iwama A, Oguro H, Negishi M et al (2004) Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 21:843–851PubMedCrossRefGoogle Scholar
  15. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedCrossRefGoogle Scholar
  16. Kim JH, Yoon SY, Jeong SH et al (2003) Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13:383–388CrossRefGoogle Scholar
  17. Kim JH, Yoon SY, Kim CN et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224PubMedCrossRefGoogle Scholar
  18. Leung C, Lingbeek M, Shakhova O et al (2004) Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428:337–341PubMedCrossRefGoogle Scholar
  19. Levine SS, King IF, Kingston RE (2005) Division of labor in polycomb group repression. Trends Biochem Sci 29:478–485CrossRefGoogle Scholar
  20. Liu JH, Song LB, Zhang X et al (2008) Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol (in press)Google Scholar
  21. Lowe SW, Sherr CJ (2003) Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13:77–83PubMedCrossRefGoogle Scholar
  22. Lund AH, van Lohuizen M (2004) Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16:239–246PubMedCrossRefGoogle Scholar
  23. Mihara K, Chowdhury M, Nakaju N et al (2006) Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 107:305–308PubMedCrossRefGoogle Scholar
  24. Molofsky AV, He S, Bydon M et al (2005) Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 19:1432–1437PubMedCrossRefGoogle Scholar
  25. Nowak K, Kerl K, Fehr D et al (2006) BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 34:1745–1754PubMedCrossRefGoogle Scholar
  26. Park IK, Qian D, Kiel M et al (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423:302–305PubMedCrossRefGoogle Scholar
  27. Raaphorst FM (2005) Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 14:R93–R100PubMedCrossRefGoogle Scholar
  28. Raaphorst FM, van Kemenade FJ, Blokzijl T et al (2000) Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin’s disease. Am J Pathol 157:709–715PubMedGoogle Scholar
  29. Sandler AB, Johnson DH, Herbst RS (2004) Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10:4258s–4262sPubMedCrossRefGoogle Scholar
  30. Satijn DP, Otte AP (1999) Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochem Biophys Acta 1447:1–16PubMedGoogle Scholar
  31. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRefGoogle Scholar
  32. Sewalt RG, van der Vlag J, Gunster MJ et al (1998) Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 18:3586–3595PubMedGoogle Scholar
  33. Silva J, García V, García JM et al (2008) Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res (in press)Google Scholar
  34. Silvestri GA, Rivera MP (2005) Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128:3975–3984PubMedCrossRefGoogle Scholar
  35. Shao Z, Raible F, Mollaaghababa R et al (1999) Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 98:37–46PubMedCrossRefGoogle Scholar
  36. Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 10:731–737CrossRefGoogle Scholar
  37. Song LB, Zeng MS, Liao WT et al (2006) Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 15:6225–6232CrossRefGoogle Scholar
  38. van Kemenade FJ, Raaphorst FM, Blokzijl T et al (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97:3896–3901PubMedCrossRefGoogle Scholar
  39. Vonlanthen S, Heighway J, Altermatt HJ et al (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372–1376PubMedCrossRefGoogle Scholar
  40. Wang H, Pan K, Zhang HK et al (2008) Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol (in press)Google Scholar
  41. Yu Q, Su B, Liu D et al (2007) Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549. Oligonucleotides 17:327–335PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Katerina Vrzalikova
    • 1
  • Joseph Skarda
    • 1
  • Jiri Ehrmann
    • 1
  • Paul G. Murray
    • 2
  • Eduard Fridman
    • 3
  • Jury Kopolovic
    • 3
  • Petra Knizetova
    • 1
  • Marian Hajduch
    • 4
  • Jiri Klein
    • 5
  • Vitezslav Kolek
    • 6
  • Lenka Radova
    • 7
  • Zdenek Kolar
    • 1
  1. 1.Laboratory of Molecular Pathology, Department of PathologyPalacky UniversityOlomoucCzech Republic
  2. 2.Cancer Research UK, Institute for Cancer StudiesUniversity of BirminghamBirminghamUK
  3. 3.Department of Pathology, The Chaim Sheba Medical Center and Sackler School of MedicineTel Aviv UniversityTel-AvivIsrael
  4. 4.Laboratory of Experimental Medicine, Department of PediatricsPalacky UniversityOlomoucCzech Republic
  5. 5.1st Department of Surgery, Medical FacultyPalacky UniversityOlomoucCzech Republic
  6. 6.Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and DentistryPalacky UniversityOlomoucCzech Republic
  7. 7.Department of Pediatrics, Medical FacultyPalacky UniversityOlomoucCzech Republic

Personalised recommendations